Consumption of Fruitflow® lowers blood pressure in pre-hypertensive males: a randomised, placebo controlled, double blind, cross-over study.
Main UddinDipankar BiswasAbhik GhoshNiamh O'KennedyAsim K DuttaroyPublished in: International journal of food sciences and nutrition (2017)
In order to investigate whether the angiotensin converting enzyme-inhibitory tomato extract Fruitflow® would lower blood pressure after consumption, we conducted a randomised, double-blinded, placebo-controlled human intervention study, involving 12 pre-hypertensive people in a crossover design. Consuming a single dose of 150 mg Fruitflow® resulted in a significant reduction in 24-hour average blood pressure as well as average wake-period and sleep-period SBP, compared to placebo. Other parameters related to blood pressure, such as 24-hour average mean arterial pressure, pulse pressure, heart rate, central aortic systolic pressure and radial augmentation index were also reduced. In addition, the platelet aggregation response to ADP, measured 24 hours after consuming Fruitflow®, fell significantly compared to baseline, and compared to placebo. This pilot study clearly shows the beneficial effects of Fruitflow® on two important cardiovascular risk factors, high blood pressure and platelet hyperactivity.
Keyphrases
- blood pressure
- placebo controlled
- double blind
- heart rate
- hypertensive patients
- clinical trial
- phase iii
- study protocol
- cardiovascular risk factors
- phase ii
- heart rate variability
- phase ii study
- angiotensin converting enzyme
- randomized controlled trial
- open label
- blood glucose
- angiotensin ii
- endothelial cells
- cardiovascular disease
- metabolic syndrome
- squamous cell carcinoma
- oxidative stress
- physical activity
- radiation therapy
- skeletal muscle
- heart failure
- pulmonary artery
- left ventricular
- depressive symptoms
- atrial fibrillation
- coronary artery